LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles). According to GlobalData, Phase I drugs for Herpes Zoster (Shingles) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LZ-901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LZ-901 overview
LZ-901 is under development for the prevention of herpes zoster infections. It is administered by intramuscular route. The vaccine candidate is being developed based on bispecific antibody development technology platform (Fabite).
Beijing Luzhu Biotechnology overview
Beijing Luzhu Biotechnology, a subsidiary of Chongqing Zhifei Biological Products Co Ltd, is a biotechnology company focused on manufacture and development of human vaccines and therapeutic biologics to develop multiple polysaccharide-protein conjugate vaccines, polysaccharide vaccines and virus inactivated vaccines. The company is headquartered in Beijing City, Beijing, China.
For a complete picture of LZ-901’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
